Molecular PSMA Imaging and Targeted Radionuclide Therapy of Metastatic Prostate Cancer

The uses of molecular imaging for targeted cancer therapyПодробнее

Molecular and Multi Modality Imaging and Theranostics of Prostate Cancer Current State of the ArtПодробнее

Theranostics Center of Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad BerkaПодробнее

Molecular Imaging of Prostate CancerПодробнее

Tumor targeted radiopharmaceuticals, Deborah Charych, co-founder of RayzeBio, Inc,Подробнее

Molecular Imaging For Staging and Advanced Disease – Axumin and PSMAПодробнее

Personalized Cancer Therapy: Using PSMA Radioligand Therapy of Metastatic Prostate CancerПодробнее

Dr. Tagawa on Remaining Questions With PSMA-Targeted Radionuclide Therapy in mCRPCПодробнее

Molecular Imaging and Targeted Radionuclide Therapy - SNMMI 2017Подробнее

177Lu-PSMA-617 radionuclide therapy in mCRPCПодробнее

PSMA-Targeted Therapy in Prostate CancerПодробнее

VISION: Lu-177-PSMA-617 in mCRPCПодробнее

177Lu-PSMA-617 for prostate cancer: TheraP, VISION, UpFrontPSMA and LuTectomyПодробнее

Dr. Tagawa on BRCA2 in Patients with Prostate Cancer Receiving PSMA-Targeted Radionuclide TherapyПодробнее

Unanswered questions in PSMA-targeted radionuclide therapyПодробнее

PSMA-Targeted Imaging in Prostate CancerПодробнее

PSMA and beyond PSMA for Prostate CancerПодробнее

The use of PSMA PET-CT scans in metastatic prostate cancerПодробнее

PSMA for Prostate Cancer -Quick OverviewПодробнее

Emerging Role of PSMA Based RadiopharmaceuticalsПодробнее

PSMA-TRT, 225Ac-J591 and 177Lu-PSMA I&T in mCRPCПодробнее